Regenxbio (RGNX) said Tuesday that the US Food and Drug Administration has accepted and granted priority review to a biologics license application for clemidsogene lanparvovec, or RGX-121, to potentially treat mucopolysaccharidosis II, also known as Hunter syndrome.
The FDA has set a target action date of Nov. 9, the company said.
The drug earlier received orphan drug product, rare pediatric disease, fast track, and regenerative medicine advanced therapy designations from the FDA as well as an advanced therapy medicinal products classification from the European Medicines Agency, Regenxbio said.
Hunter syndrome is a rare genetic disease which can lead to severe developmental delays in children.
Shares of Regenxbio were up more than 6% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。